Amarin Corp Plc (AMRN)

[ziploc_1]

Patients ignorant of the superiority of Vascepa are buying either gV, which is slightly cheaper than Vascepa....or Lovaza, which is much cheaper than both V or gV...so gV competition is more with Lovaza than with Vascepa.

If your main focus is the price, rather than your health, then you buy Lovaza...Europe deserves credit for taking Lovaza off the market, while Lovaza is still unaccountably outselling Vascepa in the U.S.

Amarin has never, to date, adequately explained to the public why they are wasting their money on Lovaza.